Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Celldex Therapeutics, Inc. (CLDX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$28.27-5.55%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CLDX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain sufficient cash to fund operations through 2028 | Celldex aims to keep enough cash to fund operations through 2028. | Improving | Cash reserves fall below levels needed to fund operations through 2028 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotechnology business, not a profitable compounder today. The thesis is in a watch state: barzolvolimab is progressing, but recent performance trails its industry cohort and the overall risk label has risen to elevated.
The evidence snapshot does not provide a valuation level or a clear account of what investors already assume, so the expectations gap is hard to assess. The company remains loss-making, and no valuation comparison with peers is available.
Near term, barzolvolimab’s Phase 3 CSU trials completed enrollment early, with topline data expected in late 2026 and a BLA submission planned for 2027; management’s timeline is on track. Cash increased after an April offering, and management says liquidity should fund operations through 2028, though the company remains loss-making and recent results have been mixed.
The multi-year thesis depends on barzolvolimab’s upcoming data and the planned regulatory filing, as well as whether CDX-622 continues to advance beyond its early clinical work. Near-term setbacks could include a guidance cut or weaker economic data; continued strength among healthcare bellwethers could support the sector backdrop.
Over the next 1 to 3 years, CLDX’s case depends on turning clinical progress and available cash into successful development and commercialization, while elevated risk and losses remain central. The evidence supports a watchful, uncertain long-term thesis. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| It focuses on managing operating losses, which were -$84.4M in 2026-Q1. |
| Intact |
| Operating losses worsen or remain at or below -$84M over next 4 quarters |
Operating income: $-80.623M FY2026-Q2; GAAP. Published target: Operating losses improve from -$84.4M in 2026-Q1 toward smaller deficits over next 4 quarters. Target period is not explicitly aligned with this observation. Aug 6, 2026-80,623,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “R&D Expenses: Research and development (R&D) expenses were $67.5 million in the second quarter of 2026 and $140.5 million for the six months ended June 30, 2026, compared to $54.2 million and $106.8 million for the comparable periods in 2025.” “The increase in R&D expenses was primarily due to an increase in barzolvolimab clinical trial and contract manufacturing expenses and an increase in employee headcount.” Delivery assessment Nov 4, 2026 |
Revenue growth from $2.63B in 2026 to $11.96B in 2027 | A primary condition in Celldex Therapeutics, Inc.'s published investment case. The stated target is Revenue grows to at least $11.96B in FY27. | Intact | Revenue falls below $2.6B in FY26 or fails to grow toward $11.96B in FY27 | Revenue: $22,000 FY2026-Q2; GAAP. Published target: Revenue grows to at least $11.96B in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 202622,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-4.44 → $-4.23 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-4.44 | $11,042,330 | 10 / 13 |
| 2026-07-25 | $-4.44 | $11,042,330 | 10 / 13 |
| 2026-07-26 | $-4.44 | $11,042,330 | 10 / 13 |
| 2026-07-27 | $-4.44 | $11,042,330 | 10 / 13 |
| 2026-07-28 | $-4.44 | $11,042,330 | 10 / 13 |
| 2026-07-29 | $-4.35 | $11,042,330 | 9 / 9 |
| 2026-07-30 | $-4.44 | $11,042,330 | 10 / 13 |
| 2026-07-31 | $-4.35 | $11,042,330 | 9 / 10 |
| 2026-08-01 | $-4.37 | $11,042,330 | 11 / 13 |
| 2026-08-02 | $-4.37 | $11,042,330 | 11 / 13 |
| 2026-08-03 | $-4.37 | $11,042,330 | 11 / 13 |
| 2026-08-04 | $-4.35 | $11,042,330 | 9 / 10 |
| 2026-08-05 | $-4.35 | $11,042,330 | 9 / 10 |
| 2026-08-06 | $-4.35 | $11,042,330 | 9 / 10 |
| 2026-08-07 | $-4.35 | $11,042,330 | 9 / 10 |
| 2026-08-08 | $-4.27 | $9,513,880 | 11 / 11 |
| 2026-08-09 | $-4.35 | $11,042,330 | 9 / 10 |
| 2026-08-10 | $-4.35 | $11,042,330 | 9 / 10 |
| 2026-08-11 | $-4.18 | $10,030,700 | 11 / 8 |
| 2026-08-12 | $-4.35 | $11,042,330 | 9 / 10 |
| 2026-08-13 | $-4.16 | $11,921,110 | 11 / 12 |
| 2026-08-14 | $-4.35 | $11,042,330 | 9 / 10 |
| 2026-08-15 | $-4.35 | $11,042,330 | 9 / 9 |
| 2026-08-16 | $-4.35 | $11,042,330 | 9 / 9 |
| 2026-08-17 | $-4.35 | $11,042,330 | 9 / 9 |
| 2026-08-18 | $-4.35 | $11,042,330 | 9 / 9 |
| 2026-08-19 | $-4.35 | $11,042,330 | 9 / 9 |
| 2026-08-20 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-08-21 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-08-22 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-08-23 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-08-24 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-08-25 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-08-26 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-08-27 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-08-28 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-08-29 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-08-30 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-08-31 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-09-01 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-09-02 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-09-03 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-09-04 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-09-05 | $-4.16 | $11,004,099 | 9 / 9 |
| 2026-09-06 | $-4.16 | $11,004,099 | 9 / 8 |
| 2026-09-07 | $-4.16 | $11,004,099 | 9 / 8 |
| 2026-09-08 | $-4.19 | $11,667,774 | 9 / 8 |
| 2026-09-09 | $-4.19 | $11,667,774 | 9 / 8 |
| 2026-09-10 | $-4.19 | $11,667,774 | 8 / 8 |
| 2026-09-11 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-12 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-13 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-14 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-15 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-16 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-17 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-18 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-19 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-20 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-21 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-22 | $-4.21 | $9,813,929 | 8 / 8 |
| 2026-09-23 | $-4.22 | $9,954,501 | 8 / 8 |
| 2026-09-24 | $-4.22 | $9,954,501 | 8 / 8 |
| 2026-09-25 | $-4.22 | $9,954,501 | 8 / 8 |
| 2026-09-26 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-09-27 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-09-28 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-09-29 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-09-30 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-01 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-02 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-03 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-04 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-05 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-06 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-07 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-08 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-09 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-10 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-11 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-12 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-13 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-14 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-15 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-16 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-17 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-18 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-19 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-20 | $-4.22 | $9,954,501 | 8 / 9 |
| 2026-10-21 | $-4.23 | $8,759,642 | 8 / 9 |
| 2026-10-22 | $-4.23 | $8,759,642 | 8 / 9 |
| 2026-10-23 | $-4.23 | $8,759,642 | 8 / 9 |
| 2026-10-24 | $-4.23 | $8,759,642 | 8 / 8 |
| 2026-10-25 | $-4.23 | $8,759,642 | 8 / 8 |
| 2026-10-26 | $-4.23 | $8,759,642 | 8 / 8 |
| 2026-10-27 | $-4.23 | $8,759,642 | 8 / 8 |
| 2026-10-28 | $-4.23 | $8,759,642 | 8 / 8 |
| 2026-10-29 | $-4.23 | $8,759,642 | 8 / 8 |
| 2026-10-30 | $-4.23 | $8,759,642 | 8 / 8 |
| 2026-10-31 | $-4.23 | $8,759,642 | 8 / 8 |
| 2026-11-01 | $-4.23 | $8,759,642 | 8 / 8 |
| 2026-11-02 | $-4.23 | $8,759,642 | 8 / 8 |
| 2026-11-03 | $-4.23 | $8,759,642 | 8 / 8 |
| 2026-11-04 | $-4.23 | $8,759,642 | 8 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 14 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.